Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Insulet Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $9.3B |
|---|
| Revenue (ttm) | 3.1B |
|---|
| Net income (ttm) | 375.3M |
|---|
| EPS (ttm) | $5.30 |
|---|
| Shares out | 69.4M |
|---|
| P/E (trailing) | 28.1x |
|---|
| P/E (forward) | 55.0x |
|---|
| Volume | 686,221 |
|---|
| Beta | 1.10 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $1.04B | $1.06B | $1.70B | $2.07B | $2.71B | +27.0% |
| Gross profit | $752.1M | $805.6M | $1.16B | $1.45B | $1.94B | +26.7% |
| Operating income | $126.0M | $37.6M | $220.1M | $308.9M | $473.8M | +39.3% |
| Net income | $16.8M | $4.6M | $206.3M | $418.3M | $247.1M | +95.8% |
| EPS (diluted) | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 | +95.1% |
| EBITDA | $139.6M | $109.0M | $323.6M | $423.7M | $509.6M | +38.2% |
| R&D | $160.1M | $180.2M | $205.0M | $219.6M | $301.1M | +17.1% |
| SG&A | $466.0M | $587.8M | $734.8M | $917.2M | $1.17B | +25.7% |
Recent company headlines from major financial publishers.
The modal expected path reflects consensus-aligned execution: FY2026 revenue of $3,287.08M (21.38% growth) and FY2027 revenue of $3,735.00M (13.63% growth), guided by mid-teens exit growth. Operating margins expand ~100 basis points annually from 17.5% in FY2025 to 22.5% by FY2030, supporting diluted EPS of $6.51 in FY2026 and $7.73 in FY2027, yielding our house Fair value of $164.82.
Accelerated adoption of Omnipod 5 across intensive and basal Type 2 diabetes segments combines with rapid international expansion, driving consolidated top-line growth above 25% annually. Automated manufacturing lines achieve optimal yield efficiencies, expanding operating margins beyond 24% and compounding diluted EPS above 25% annually toward our high-case valuation of $210.43,.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 8.5% | $171 | $177 | $184 | $193 | $203 |
| 9.0% | $163 | $168 | $174 | $181 | $189 |
| 9.5% | $156 | $160 | $165 | $171 | $177 |
| 10.0% | $149 | $153 | $157 | $162 | $168 |
| 10.5% | $143 | $147 | $150 | $154 | $159 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
